Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.65 |
| ▸ | CCR3 | P51677 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.60 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.56 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.56 |
| ▸ | SCN4A | P35499 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184584 | 0.89 | CCR3 (0.62) | LTA4HCCR3CTNNB1TCF7L2KMT2A | |
| SCHEMBL6154047 | 0.86 | LTA4H (0.67) | LTA4HCCR3ROCK2ROCK1 | |
| SCHEMBL1554194 | 0.84 | TDP1 (0.61) | LTA4HCCR3ROCK2ROCK1 | |
| SCHEMBL30182449 | 0.81 | KMT2A (0.74) | KMT2A | |
| SCHEMBL2579208 | 0.81 | KMT2A (0.74) | KMT2A | |
| SCHEMBL30182461 | 0.81 | KMT2A (0.74) | KMT2A | |
| SCHEMBL8094101 | 0.81 | POLB (0.65) | CCR3ROCK2ROCK1KMT2A | |
| SCHEMBL28410341 | 0.80 | MEN1 (0.61) | KMT2A | |
| SCHEMBL11370228 | 0.79 | AOC3 (0.63) | KMT2A | |
| SCHEMBL22470297 | 0.78 | MEN1 (0.62) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | TCF4, CTNNB1, TCF7 | LTA4H 3037/4885CCR3 3024/4885ROCK2 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.